Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jan Wijnholds, Elizabeth C.M. de Lange, George L. Scheffer, Dirk-Jan van den Berg, Carla A.A.M. Mol, Martin van der Valk, Alfred H. Schinkel, Rik J. Scheper, Douwe D. Breimer, Piet Borst
Published in Volume 105, Issue 3
J Clin Invest. 2000; 105(3):279–285 doi:10.1172/JCI8267
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3

Increased accumulation of etoposide into the CSF of mice lacking Mrp1 (TKO mice) compared with mice containing Mrp1 (DKO mice). Brain vesicles were cannulated and then perfused with artificial CSF. Etopophos® (60 mg/kg) was administered via a tail vein; CSF was collected for 1 hour after drug administration, and the etoposide concentration was determined. (a) The TKO mice (n = 5) accumulated 10-fold more etoposide in the CSF than did the DKO mice (n = 4) (8.1 ± 0.9 μM and 0.8 ± 0.3 μM, respectively; P < 0.001), whereas levels in total brain (3.9 ± 0.7 μmol/kg [n = 5] and 2.9 ± 0.7 μmol/kg [n = 4], TKO and DKO mice, respectively) did not differ significantly 1 hour after drug administration. (b) Etoposide levels in plasma (98 ± 12 μM [n = 5] and 114 ± 24 μM [n = 4], TKO and DKO mice, respectively) did not differ significantly 1 hour after drug administration.